U.S. markets closed

Has Coherus BioSciences (CHRS) Outpaced Other Medical Stocks This Year?

Zacks Equity Research

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Coherus BioSciences (CHRS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of CHRS and the rest of the Medical group's stocks.

Coherus BioSciences is a member of the Medical sector. This group includes 883 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. CHRS is currently sporting a Zacks Rank of #1 (Strong Buy).

The Zacks Consensus Estimate for CHRS's full-year earnings has moved 53.01% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.

According to our latest data, CHRS has moved about 98.67% on a year-to-date basis. At the same time, Medical stocks have gained an average of 9.80%. This means that Coherus BioSciences is performing better than its sector in terms of year-to-date returns.

Breaking things down more, CHRS is a member of the Medical - Biomedical and Genetics industry, which includes 374 individual companies and currently sits at #62 in the Zacks Industry Rank. On average, stocks in this group have gained 8.67% this year, meaning that CHRS is performing better in terms of year-to-date returns.

Investors in the Medical sector will want to keep a close eye on CHRS as it attempts to continue its solid performance.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Coherus BioSciences, Inc. (CHRS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.